BPX 701 - Bellicum Pharmaceuticals/Leiden university Medical Center

Drug Profile

BPX 701 - Bellicum Pharmaceuticals/Leiden university Medical Center

Alternative Names: BPX701

Latest Information Update: 21 Mar 2017

Price : $50

At a glance

  • Originator Leiden University Medical Center
  • Developer Bellicum Pharmaceuticals; Leiden University Medical Center
  • Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunostimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Myelodysplastic syndromes
  • Preclinical Malignant melanoma; Neuroblastoma; Sarcoma; Uveal melanoma

Most Recent Events

  • 01 Mar 2017 Phase-I clinical trials in Acute myeloid leukaemia (Treatment-resistant, Recurrent) in USA (IV) (NCT02743611)
  • 01 Mar 2017 Phase-I clinical trials in Myelodysplastic syndromes (Treatment-resistant, Recurrent) in USA (IV) (NCT02743611)
  • 08 Aug 2016 US FDA approves IND application for BPX 701 in Acute myeloid lukaemia and Myelodysplastic Syndrome
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top